Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities

Cash Flow Statement

Daily Values

Growth Metrics

Arcadia Biosciences (RKDA) Notes Payables (2019 - 2020)

Arcadia Biosciences filings provide 4 years of Notes Payables readings, the most recent being $31000.0 for Q1 2020.

On a quarterly basis, Notes Payables changed N/A to $31000.0 in Q1 2020 year-over-year; TTM through Mar 2020 was $31000.0, a N/A change, with the full-year FY2019 number at $24000.0, changed N/A from a year prior.
Notes Payables hit $31000.0 in Q1 2020 for Arcadia Biosciences, up from $24000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $137000.0 in Q3 2019 to a low of $24000.0 in Q4 2019.